PHARMACOKINETICS. Dr. M.Mothilal Assistant professor

Similar documents
Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal

SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS

BIOPHARMACEUTICS AND PHARMACOKINETICS

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics

Dr. M.Mothilal Assistant professor

BIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season

Study (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética

Oral Delivery of Drugs

PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models

Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D

Injectable modified release products

Fig. 4. A two-compartment pharmacokinetic model.

II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week THEORY

Unit V APPLICATIONS OF PHARMACOKINETICS

In silico Prediction of Bioavailability of Pharmaceutical Formulations Using Population Pharmacokinetic Model Simulation

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?

Pharmacokinetic & Pharmacodynamic Data Analysis

UNIT 2. Drug Distribution. S. SANGEETHA., M.PHARM., (Ph.d) Department of Pharmaceutics SRM College of Pharmacy SRM University

On applications of conservation laws in pharmacokinetics

Lipoidal permeability central to drug ADME Major barriers to drug discovery: dogma surrounding plasma protein binding and tissue concentration

Biomath M263 Clinical Pharmacology

Official Letter from the DOH

Mechanistic IVIVC Using the Simcyp ADAM Model. Make SCIENCE out of IVIVC

INTRODUCTION TO PHARMACOLOGY

Pharmacokinetics in clinical oncology

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

Application of PBPK Models in Assessment of Bioequivalence

INTRODUCTION TO CLINICAL PHARMACY

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1

Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997

Eurofins ADME BIOANALYSES Your partner in drug development

Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists

Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC

Design and Dosage Form. Dr. Deny Susanti

Compartmental Pharmacokinetic Analysis. Dr Julie Simpson

Toxicokinetic models and their applications

Science and Quality Assurance, Part 2: PK/QA

NORTH CAROLINA STATE UNIVERSITY Raleigh, North Carolina

The views and opinions expressed in the following PowerPoint slides are

Application of Direct Search Optimization for Pharmacokinetic Parameter Estimation

Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics

Chimica Farmaceutica. Pharmacokinetics and related topics

Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation

CHAPTER 4: PHARMACOKINETICS. 1. Choice of a suitable drug, and 2. A balance between the therapeutic and the toxic effects.

Clinically Relevant Specifications (CRS): A Regulatory Perspective

Current Guidelines for Drug-drug Interaction Evaluation

Bioavailability and Bioequivalence Studies

Clinical Pharmacokinetics The Mcq Approach Telford Press

PHARMACOKINETICS OF DROPERIDOL IN SURGICAL PATIENTS UNDER DIFFERENT CONDITIONS OF ANAESTHESIA

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase

The relevance of dissolution testing for trimetazidine

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis

Making PK Analysis Easier: The New ADaM Data Standard ADNCA

KEY WORDS Pharmacokinetics, modeler, hands-on, safety, practical class, clinical training.

Dermal drug testing. Pharmacokinetic, pharmacodynamic and bioequivalence studies in the dermis

MEDICINES CONTROL COUNCIL

Pharmacokinetic / pharmacodynamic modeling and simulation in the design and analysis of Randomized Concentration-Controlled Trials (RCCTs)

Faculty : Pharmacy Department: Pharmaceutical Sciences and Pharmaceutics Academic Year: Semester : Second ( Course Syllabus )

Comparison of the pharmacokinetics of chloroquine after single

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

In Vitro-In Vivo Correlation:

Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator

Guideline on quality of oral modified release products

BIOEQUIVALENCE: BLOOD LEVEL BIOEQUIVALENCE STUDY

RE: CPMT Pharmacokinetic Analyses of Fixed-Dose Drug Combinations for Pediatric Tuberculosis

The general concept of pharmacodynamics

KEYWORDS: Pharmaceutical Engineering, Chemical Engineering, Pharmaceutical Industry, Master Degree, Graduate Studies.

Biology 137 Introduction to Toxicology Fall Which of the following would enhance the excretion of xenobiotic molecules?

Introduction to Pharmacokinetic Modeling

Pharmacokinetics of PROTEIN DRUGS

A. TRIAL IDENTIFICATION

Line extension of immediate release products

ORAL BIOAVAILABILITY ASSESSMENT

Guideline on quality of oral modified release products

Phys Lab Protocols BLOCK 2. Pharmacokinetics, Compartments ECG Blood Pressure and Heart Spirometry. v

Assessment of BE. Assessment of bioequivalence of implants: Appropriate study design, metrics, and acceptance criteria

Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications

EVALUATION OF THE SAFETY OF VETERINARY MEDICINAL PRODUCTS FOR THE TARGET ANIMALS

MODERN MEDICINAL CHEMISTRY

In vitro in vivo correlations (IVIVC) can be summarized

Guidance for Industry

Revised guideline on the conduct of bioequivalence studies for veterinary medicinal products

VICH GL52 on Bioequivalence: blood level bioequivalence study

Target-mediated drug disposition model for drugs that bind to more than one target

Organic Pharmaceutical Chemistry: Prodrugs

Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA

Σχεδιασμός κλινικών μελετών βιοϊσοδυναμίας (DESIGN OF BIOEQUIVALENCE STUDIES) To demonstrate that two (or more) medicinal products are bioequivalent

Translational Pharmaceutics : a unique platform to accelerate early oncology development

PBPK A Platform for Bridging People & Knowledge in Early Drug Development Club Phase I workshop PBPK: A new Paradigm in Drug Development Neil Miller

drug discovery: Where are we now? How did we RSC February 2013

Basic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials

The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data

Session 7 Clinical Trial Assessment Bioequivalence Studies

Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD

Transcription:

PHARMACOKINETICS Dr. M.Mothilal Assistant professor 1

OVERVIEW Basic considerations in pharmacokinetics Compartment models One compartment model Assumptions Intravenous bolus administration Intravenous infusion Extravascular administration (zero order and first order absorption model) References 2

BASIC CONSIDERATIONS IN PHARMACOKINETICS Pharmacokinetic parameters Pharmacodynamic parameters Zero order kinetic First order kinetic Mixed order kinetic Compartment model Non compartment model Physiologic model 3

Pharmacokinetic models Means of expressing mathematically or quantitatively, time course of drug through out the body and compute meaningful pharmacokinetic parameters. Useful in : Characterize the behavior of drug in patient. Predicting conc. of drug in various body fluids with dosage regimen. Calculating optimum dosage regimen for individual patient. Evaluating bioequivalence between different formulation. Explaining drug interaction. 4

5 Compartment models

OBJECTIVE To understand the assumptions associated with the one compartment model To understand the properties of first order kinetics and linear models To write the differential equations for a simple pharmacokinetic model To derive and use the integrated equations for a one compartment linear model To define, use, and calculate the parameters, Kel (elimination rate constant), t1/2 (half-life), Cl (clearance), V (apparent volume of distribution), and AUC (area under the concentration versus time curve) as they apply to a one compartment linear model 6

OPEN and CLOSED models: The term open itself mean that, the administered drug dose is removed from body by an excretory mechanism ( for most drugs, organs of excretion of drug is kidney) If the drug is not removed from the body then model refers as closed model. 7

8 One Compartment

PHARMACOKINETICS Pharmacokinetics is the study of drug and/or metabolite kinetics in the body. The body is a very complex system and a drug undergoes many steps as it is being absorbed, distributed through the body, metabolized or excreted (ADME). 9

10

Assumptions 1. One compartment The drug in the blood is in rapid equilibrium with drug in the extravascular tissues. This is not an exact representation however it is useful for a number of drugs to a reasonable approximation. 11

2. Rapid Mixing We also need to assume that the drug is mixed instantaneously in blood or plasma. 3. Linear Model We will assume that drug elimination follows first order kinetics. 12

Linear Model - First Order Kinetics First-order kinetics 13

14 This behavior can be expressed mathematically as :

One compartment model One compartment model can be defined : One com. open model i.v. bolus. One com. open model - cont. intravenous infusion. One com. open model - extra vas. administration ( zero-order absorption) One com. open model - extra vas. Administration ( first-order absorption ) 15

16 One Compartment Model, Intravenous (IV) Bolus Administration

Rate of drug presentation to body is: dx = rate in (availability) rate out (elimination) dt Since rate in or absorption is absent, equation becomes dx = - rate out dt If rate out or elimination follows first order kinetic dx/dt = -k E X (eq.1) 17

Elimination phase: Elimination phase has three parameters: Elimination rate constant Elimination half life Clearance 18

Elimination rate constant Integration of equation (1) ln X = ln Xo K E t (eq.2) Xo = amt of drug injected at time t = zero i.e. initial amount of drug injected X=Xo e -KEt ( eq.3) log X= log Xo K E t 2.303 (eq.4) 19

Since it is difficult to directly determine amount of drug in body X, we use relationship that exists between drug conc. in plasma C and X; thus X = V d C (eq. 5) So equation-8 becomes log C = log Co K E t 2.303 (eq.6) 20 25 November 2010

K E = Ke + Km +Kb +Kl +.. (eq.7) K E is overall elimination rate constant 21 25 November 2010

Elimination half life t 1/2 = 0.693 K E (eq.8) Elimination half life can be readily obtained from the graph of log C versus t Half life is a secondary parameter that depends upon the primary parameters such as clearance and volume of distribution. t 1/2 = 0.693 V d Cl T (eq.9) 22

Apparent volume of distribution Defined as volume of fluid in which drug appears to be distributed. Vd = amount of drug in the body = X plasma drug concentration C (eq.10) Vd = Xo/Co =i.v.bolus dose/co (eq.11) E.g. 30 mg i.v. bolus, plasma conc.= 0.732 mcg/ml. Vol. of dist. = 30mg/0.732mcg/ml =30000mcg/0.732mcg/ml = 41 liter. 23

For drugs given as i.v.bolus, V d (area)=xo/k E.AUC.12.a For drugs admins. Extra. Vas. V d (area)=f Xo/K E.AUC..12.b 24

Clearance Clearance = rate of elimination plasma drug conc.. Or Cl= dx /dt C (eq.13) Thus Renal clearance = rate of elimination by kidney C Hepatic clearance = rate of elimination by liver C Other organ clearance = rate of elimination by organ C Total body clearance: Cl T = Cl R + Cl H + Cl other (eq.14) 25 KLECOP, Nipani 25 November 2010

According to earlier definition Cl = dx /dt C Submitting eq.1 dx/dt = K E X, above eq. becomes Cl T = K E X/ C (eq 15) By incorporating equation 1 and equation for vol. of dist. ( Vd= X/C ) We can get Cl T =K E Vd (eq.16) 26 KLECOP, Nipani 25 November 2010

Parallel equations can be written for renal and hepatic clearance. Cl H =Km Vd (eq.17) Cl R =Ke Vd (eq.18) but K E = 0.693/t 1/2 so, Cl T = 0.693 Vd (eq.19) t 1/2 27

For non compartmental method which follows one compartmental kinetic is : For drug given by i.v. bolus Cl T = Xo..20.a AUC For drug administered by e.v. Cl T = F Xo..20.b AUC For drug given by i.v. bolus renal clearance = Xu (eq. 21) AUC 28

Organ clearance Rate of elimination by organ= rate of presentation to the organ rate of exit from the organ. Rate of elimination =Q. C in -Q.C out (rate of extraction) =Q (C in -C out ) Cl organ =rate of extraction/c in =Q(C in -C out )/C in =Q.ER.(eq 22) Extraction ratio: ER= (C in -C out )/ C in ER is an index of how efficiently the eliminating organ clear the blood flowing through it of drug. 29

According to ER, drugs can be classified as- Drugs with high ER (above 0.7) Drugs with intermediate ER (between 0.7-0.3) Drugs with low ER (below 0.3) The fraction of drug that escapes removal by organ is expressed as F= 1- ER where F= systemic availability when the eliminating organ is liver. 30

Hepatic clearance Cl H = Cl T Cl R o Can also be written down from eq 22 o Cl H = Q H ER H o Q H = hepatic blood flow. ER H = hepatic extraction ratio. o Hepatic clearance of drug can be divided into two groups : 1. Drugs with hepatic blood flow rate-limited clearance 2. Drugs with intrinsic capacity- limited clearance 31

Hepatic blood flow F=1-ER H = AUC oral AUC i.v 32

Intrinsic capacity clearance Denoted as Cl int, it is defined as the inherent ability of an organ to irreversibly remove a drug in the absence of any flow limitation. 33

One compartment open model: Intravenous infusion Model can be represent as : ( i.v infusion) Drug R 0 Zero order Infusion rate dx/dt=r o -K E X eq 23 X=R o /K E (1-e -KEt ) eq 24 Since X=V d C C=R o /K E Vd(1-e -KEt ) eq 25 =R o /Cl T (1-e -KEt ) eq 26 Blood & other Body tissues K E 34

At steady state. The rate of change of amount of drug in the body is zero,eq 23 becomes Zero=R o -K E X SS 27 K E X SS =R o 28 C SS =R o /K E V d 29 =R o /Cl T i.e infusion rate...30 clearance Substituting eq. 30 in eq. 26 C=C SS (1-e -KEt ) 31 Rearrangement yields: [C SS -C]=e -KEt....32 C SS log C SS -C = -K E t 33 C SS 2.303 35

If n is the no. of half lives passed since the start of infusion(t/t 1/2 ) Eq. can be written as C=C SS [1-(1/2) n ] 34 36

Infusion plus loading dose Xo,L=C SS V d 35 Substitution of C SS =R o /K E V d Xo,L=R o /K E 36 C=Xo,L/V d e -KEt + R o /K E V d (1-e -K Et ) 37 37

Assessment of pharmacokinetic parameter AUC=R o T/K E V d =R o T/Cl T =C SS T Where T=infusion time 38

One compartment open model : extra vascular administration When drug administered by extra vascular route (e.g. oral, i.m, rectal ), absorption is prerequisite for its therapeutic activity. 39

dx/dt=rate of absorption-rate of elimination dx /dt = dx ev /dt dx E /dt 38 dx ev /dt >dx E /dt dx ev /dt=dx E /dt dx ev /dt<dx E /dt 40

One compartment model: extra vascular admin ( zero order absorption) This model is similar to that for constant rate infusion. Blood & other Drug at site R0 Body tissues Elimination zero order absorption o Rate of drug absorption as in case of CDDS, is constant and continues until the amount of drug at the absorption site (e.g. GIT) is depleted. o All equations for plasma drug conc. profile for constant rate i.v. infusion are also applicable to this model. 41

One compartment model: extra vascular admin ( first order absorption) Drug that enters the body by first order absorption process gets distributed in the body according to one compartment kinetic and is eliminated by first order process. The model can be depicted as follows: Drug at site K a First order Blood & other Body tissues K E elimination absorption 42

The differential form if eq. 38 is dx/ dt=k a X a -K E X 39 X=K a FX o /K a -K E [e -KEt -e -Kat ] 40 C=K a F X o /V d (K a -K E )[e -KEt -e -Kat ] 41 43

References : Biopharmaceutics and pharmacokinetics. P L Madan, page no.73-105, 1 st edn. Biopharmaceutics and pharmacokinetics. D.M Brahmankar and Sunil. B.Jaiswal, page no.212-259,1 st edn Applied Biopharmaceutics and pharmacokinetics Leon shargel and Andrew Yu, page no. 47-62 4 th edn. Biopharmaceutics and clinical pharmacokinetics By Milo Gibaldi, page no.14-23, 4 th edn. 44